PRIME Time in Rheumatoid Arthritis
Identification of preinflammatory mesenchymal, or PRIME, cells — that appeared in blood just before disease flares, by sequential RNA analysis before and during flares of RA
Roflumilast Cream for Chronic Plaque Psoriasis
Roflumilast cream contains a PDE-4 inhibitor
The mean baseline PASI scores were 7.7 in the roflumilast 0.3% group, 8.0 in the roflumilast 0.15% group, and 7.6 in the vehicle group; the mean change from baseline at week 6 was −50.0%, −49.0%, and −17.8%
Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus
Nemolizumab is a subcutaneously administered humanized monoclonal antibody against interleukin-31 receptor A
The median VAS score (0-to-100 scale when the baseline score is 100)
for pruritus at baseline was 75. At week 16, the mean percent change in the VAS score was −42.8% in the nemolizumab group and −21.4% in the placebo group
The mean percent change in the EASI (0-72) score was −45.9% with nemolizumab and −33.2% with placebo.
DLQI score of 4 or less was 40% in the nemolizumab group and 22% in the placebo group
DLQI; (range, 0 to 30, with higher scores indicating a greater effect on daily life)